Background:  This is a phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of CSL112 on reducing the risk of major adverse CV events [MACE - cardiovascular (CV) death, myocardial infarction (MI), and stroke] in subjects with acute coronary syndrome (ACS) diagnosed with either ST-segment elevation myocardial infarction (STEMI) or non-ST-segment elevation myocardial infarction (NSTEMI), including those managed with percutaneous coronary intervention (PCI) or medically managed. Trial Registration No: NCT03473223 (clinicaltrials.gov) Link  Sponsor:  CSL Behring  Trial Status: recruiting  Enrolling Centers:  Worldwide: 17400 participants Core Study Team Basel:
© Christian Mueller, 2012 - 2019 │  Disclaimer  │  Imprint  │  Webmaster │ Last Update: October 2019
Home News Team Studies Publications Events Cooperations Contact Kristin Shrestha Beate Hartmann Ph.D. Dr. Dayana Flores Dr. Matthias Diebold Ina-Maria Ferel-Harwerth, Ph.D. Natascha Herr Michael Freese, UP Ketina Arslani Velina Widmer Rafal Czmok Prof. Danielle Gualandro Paul David Ratmann